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The virus validation of three steps of Biotest Pharmaceuticals IGIV production process is described here.
The steps validated are precipitation and removal of fraction III of the cold ethanol fractionation
process, solvent/detergent treatment and 35 nm virus ﬁltration. Virus validation was performed
considering combined worst case conditions. By these validated steps sufﬁcient virus inactivation/
removal is achieved, resulting in a virus safe product.
& 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
One of the most important clinical applications of intravenous
immunoglobulin (IGIV) is to supply antibodies to patients who
are antibody deﬁcient. Patients with inherited (primary) antibody
deﬁciencies are treated throughout their lives with relatively high
doses of IGIV. Patients who develop secondary antibody deﬁcien-
cies because of disease or disease therapy may also receive high
dose IGIV for long periods of time. Since regular exposure to
human plasma protein therapy carries the risk of infection with
blood-borne pathogens, increasing the pathogen safety of IGIV,
without diminishing its clinical efﬁcacy, is essential and required
by regulatory authorities for marketing authorization. Validation
of virus inactivation and removal should be performed in com-
pliance with current guidelines [1,2].
All plasma used for the production of Biotest IGIV1 is obtained
from licensed plasmapheresis centers. Plasma donations are made
by qualiﬁed, selected donors and all donations are carefully
screened serologically and minipools by nucleic acid ampliﬁcationogen Safety, Landsteiner Str.
; fax: þ49 6103 801 872.
e (H.O. Dichtelmu¨ller).
euticals; Boca Raton, FL, USA.
Y-NC-ND license.technique (NAT) for HIV, Hepatitis A virus (HAV), Hepatitis B virus
(HBV), Hepatitis C virus (HCV) and Parvovirus B19. As all screening
is limited by the sensitivity of the screening assays and the viruses
screened for, virus removal and inactivation during the production
of Biotest IGIV signiﬁcantly contribute to the virus safety of the
product. The steps of virus inactivation and removal of Biotest IGIV
and their efﬁcacy are described here.2. Materials and methods
2.1. Scale down
The studies were performed in compliance with current
guidelines [1,2] in a scaled-down version of the production
process using the same parameters and controls that are used
in large-scale manufacturing. Scale-down reduction factors were
based on the equipment used for virus validation studies and
considered the volumes of reaction containers, the size of ﬁlter
disks with a deﬁned ﬁltration area, the size of 35 nm ﬁlter
cartridges and the available volume of test materials. The scale
down factor for each process step was deﬁned by comparing
the production scale to virus validation scale. Scale-down
runs were performed for each production step prior to virus
validation studies, controlling the process parameters such as pH,
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n-butyl phosphate (TNBP) or Triton X-100 to demonstrate com-
parability to production scale.
2.2. Manufacturing description
The manufacturing process is illustrated in Fig. 1 and is
described as follows: the plasma is tempered at 2–8 1C for up to
16 h and the cryoprecipitate is removed by centrifugation. Cold
ethanol fractionation of the cryo poor plasma is performed,
including the most effective and crucial step of precipitation
and removal of fraction III. From resuspended fraction IIþ III,
fraction III is precipitated with 17% ethanol at 5 1C and removed
by centrifugation. The centrifugate is clariﬁed by depth ﬁltration
using ﬁlter aid, the pH is adjusted and the protein solution is
ultraﬁltered and sterile ﬁltered.
The ﬁnal IgG solution is subjected to virus inactivation using
TNBP and Triton X-100 at pH 4.25 and 28 1C for a minimum of 2 h
and solvent/detergent (S/D) is removed by C18 (Waters Corp.;
Taunton, MA, USA) chromatography. For virus ﬁltration, the IgG
solution is preﬁltered through a 0.2 mm ﬁlter, followed by a 75 nm
ﬁlter and a 35 nm ﬁlter (Planova 75 N and 35 N; Asahi Kasei
Bioprocess).Product/treatment Step
Source Plasma Removal of Cryo precipitate
↓
Cryo poor plasma
↓
Cold Ethanol 
Fractionation
Precipitation and 
removal of fraction III
from resuspended
fraction II+III
↓
Fractionated IgG 
solution
↓
Virus inactivation Solvent / Detergent Treatment
T
↓
C-18 adsorption 
Removal of S/D
Column 
Chromatography
↓
Q-Sepharose 
Purification of IgG
Column 
Chromatography
↓
Virus filtration
0.2μm prefilter
75 nm Planova 75N
35 nm Planov 35 N
↓
Filtrate
↓
Virus filtered IgG 
solution
Ultra/dia filtration, 
Final formulation, 
Sterile filtration
↓
Sterile bulk
↓
Fill
↓
Biotest IGIV Drug product
Fig. 1. Biotest IGIV production proces2.3. Process intermediates studied
Test materials for virus validation studies were produced in
the Process Development Department at Biotest Pharmaceuticals
Corporation, Boca Raton, Florida, USA, using a development scale
manufacturing process that had been validated against the full
scale manufacturing process of Biotest IGIV.
The following process steps were studied:Pr
1
p
C
de
Fil
NB
28 
p
p
s anPrecipitation and removal of fraction III and Depth Filtration.
 Treatment with TNBP–Triton X-100 (S/D treatment).
 Nanoﬁltration (35 nm virus ﬁltration).
2.4. Equipment used in scale down studies
Scale-down studies and virus validation studies were per-
formed using similar equipment. Test materials were transferred
into specially designed, double-jacketed reaction containers,
made from glass with a V-shaped bottom and connected to
cooling or heating devices. Reaction containers were equipped
with nozzles for adding test materials, reagents or for taking
samples.oduction scale Virus validation scale
7±2% ethanol, 
-5 ± 1°C,
H 5.20 ± 0.05
entrifugation,
pth filtration of 
supernatant
trate processed
15% ethanol, 
-4°C,
pH 5.15, 5.25, 5.45
Centrifugation,
depth filtration of 
supernatant
Filtrate processed
P (0.3%); Triton 
X-100 (1.0%)
± 2°C, ≥2 hours
H 4.25 ± 0.25
TNBP (0.2%); Triton 
X-100 (0.8%)
25.5°C, ≥2 hours
pH 4.50/6.20
<125 Kg/m2
22 ± 7.5 °C
H 4.20 ± 0.1
150 kg/m2
22.1-30.4°C
pH 4.10/ 6.10
d virus validation conditions.
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Human Immunodeﬁciency Virus (HIV-1): HIV was used as a
relevant virus for validation studies. The strain BRU was obtained
from Georg Speyer House, Frankfurt, Germany. The virus (RNA,
enveloped) was propagated and titrated on C8166 cells.
Pseudorabies Virus (PRV): PRV, an enveloped double-stranded
DNA virus, was used to represent the herpesviruses and was
obtained from the American Type Culture Collection (ATCC) (VR-
135; strain Aujeszky). Human herpesviruses are not suitable for
the studies due to interference by antibodies in human plasma.
For virus titration BHK cells (CCL-10) were obtained from ATCC.
Bovine Viral Diarrhea Virus (BVDV): BVDV (pestivirus) was
obtained from the ATCC (VR-534; strain NADL). For virus titration
EBTr cells (ATCC; CCL-44) were used for virus titration. BVDV,
an enveloped single-stranded RNA virus, is a model virus for
Hepatitis C Virus.
Sindbis Virus (SinV): Sindbis Virus (ATCC: VR-1248) was
obtained from Prof. Chr. Kempf, Central Laboratory of the Swiss
Red Cross, Bern. For virus titration Vero cells (ATCC: CCL 81) were
obtained from ATCC. Sindbis (an alphavirus) is an enveloped,
single-stranded RNA virus that is also used as a model for
Hepatitis C Virus.
West Nile Virus (WNV): WNV strain Uganda, obtained from
ATCC (956), is an enveloped, single-stranded RNA virus. WNV is a
relevant virus and its transmission by blood transfusion has been
reported.
Porcine Parvovirus (PPV): PPV, a non-enveloped, small single-
stranded DNA virus, was obtained from ATCC (VR-742; strain
NADL-2) and was used as a model for Parvovirus B19. PPV is
titrated on PK 13 cells (ATCC/CRL-6489) and does not cross react
with antibodies to B19 Parvovirus. Parvoviruses are highly resis-
tant to heat and to solvent/detergent treatment.
Murine Encephalomyelitis Virus (MEV): MEV was obtained from
A. Scheidler (Robert-Koch-Institute) and is used as a model virus
for Hepatitis A Virus. MEV is propagated and titrated on BHK cells
(ATCC: CCL-10). MEV is a non-enveloped, small single-stranded
RNA virus (Picorna virus) and is not neutralized by cross-reacting
antibodies to Hepatitis A virus.
Bovine Parvovirus (BPV): BPV, a small, non-enveloped single-
stranded DNA virus, was obtained from ATCC (VR-767; strain
Haden) and is used as a model virus for parvovirus B19. It is
propagated and titrated on KL-2 cells. BPV cross reacts with
antibodies to B19 Parvovirus. This virus was used for virus
ﬁltration studies to test the potential inﬂuence of neutralizing
antibodies on virus removal by virus ﬁltration.
Simian Virus 40 (SV 40): SV40 was obtained from ATCC (SV40-
PML 2, ATCC VR-821). It is highly resistant to chemical or physical
treatment. For virus titration CV-1 cells from ATCC (CCL-70) were
used. SV40, a double-stranded DNA virus, is used as a model for
non-enveloped, highly resistant DNA viruses.
2.6. Virus titration and calculation of inactivation
Virus titers, prior to and after virus reduction or virus inactiva-
tion treatment, were determined by tissue culture infectious dose
assays at 50% infectivity and calculated by the Spearman and
Kaerber method [3]. Virus titers are expressed as the negative
decadic logarithm. Virus clearance was calculated by comparing
the virus titers prior to and after the virus removal or inactivation
step.
2.7. Virus validation studies
Virus validation studies were conducted in the Pathogen
Safety Department of Biotest, Dreieich, Germany. Virus validationstudies addressed the worst case conditions (Fig. 1) assumed to be
low concentrations of alcohol in precipitation studies, reduced
S/D concentrations in inactivation studies and elevated tempera-
tures or high volumes per ﬁlter area in ﬁltration studies. Studies
per step and virus were performed at least in duplicate to
demonstrate the reproducibility of results.2.7.1. Combination of fraction III precipitation and depth ﬁltration of
fraction III supernatant
Resuspended fraction IIþ III was spiked with test virus, frac-
tion III was precipitated at assumed worst case conditions, using
15% ethanol at 4 1C. Tests were performed at pH 5.15, pH 5.25
and at pH 5.45. The precipitated fraction III was removed by
centrifugation and the supernatant was ﬁltered through a depth
ﬁlter and was tested for virus removal. Same was done without
depth ﬁltration. Precipitation of fraction III, centrifugation, ﬁltra-
tion and collection of ﬁltrate was done at 4 1C.2.7.2. Depth ﬁltration of fraction III supernatant
Fraction III supernatant (17% ethanol) was spiked with test
virus and ﬁltered at 4 1C through a Cuno SP depth ﬁlter (Cuno,
Meriden CT, USA) and tested under worst case conditions, i.e.
elevated volume per ﬁlter area of 500 kg/m2 and pH 5.10,
beyond the lower limit of production scale and at pH 5.45, beyond
upper limit.2.7.3. Solvent/detergent treatment
For S/D treatment, test material was spiked with test virus and
treated at combined worst case conditions with a reduced con-
centration of 0.2% (w/w) TNBP and 0.8% (w/w) Triton X-100 and
at a reduced temperature of 25.5 1C. The concentrations of S/D are
at the lower end of the production range. To prevent potential
inactivation of viruses by low pH during S/D treatment, runs were
performed at neutral pH 6.20.2.7.4. Virus ﬁltration with a 35 nm Planova ﬁlter
Eluate from Q Sepharose (GE Healthcare Bio-Sciences; Uppsala,
Sweden) was spiked with test virus and passed through a 75 nm
preﬁlter followed by a 35 nm ﬁlter (Asahi Kasei Bioprocess; Brussels,
Belgium) at worst case conditions, such as high temperature of
r29.5 1C, high volume per ﬁlter area (150 kg/m2) and constant high
pressure of Z0.8 to r1.0 bar. Filtration was performed in dead end
mode, where the feed is pumped directly against the ﬁlter mem-
brane without any tangential ﬂow.3. Results
3.1. Precipitation and removal of fraction III
The conditions for validation of fraction III precipitation
included lowering the ethanol concentration, shortening the
precipitation time and increasing the temperature. The virus
reductions observed at pH 5.10 are shown in Table 1 as a worst
case condition.
3.2. Depth ﬁltration of fraction III supernatant
Validation of virus removal was tested at low pH of 5.10,
reduced amount of ﬁlter aid and at a ratio of sample volume to
ﬁlter area that was higher than the ratio used in manufacturing.
Virus reductions were less than 1 log10 at every condition tested
and none of the data were used to estimate total virus clearance.
Table 1
Virus removal and inactivation during Biotest IGIV production.
Virus reduction (log10)
Enveloped viruses Non-enveloped viruses
Relevant virus HIV HBV HCV WNV B19 Parvovirus HAV Resistant
DNA viruses
Test virus HIV PRV BVDV Sindbis WNV PPV BPV MEV SV40
Fraction III precipitation and removala 1.87 2.83 o1.55 2.00
Fraction III precipitation and depth ﬁltration combineda 4.00 5.29
Solvent–detergent treatmenta 44.43 44.01 45.04 47.11 44.96b,a
35 nm Virus ﬁltrationa 45.19 44.64 44.88 o1.0 6.18 o1.0 45.02
Low pH (as part of S/D or virus ﬁltration) 2.43 3.20 o1.0 4.91 2.08 o1.0 o1.0
Total clearance (log10)
a 49.62 48.65 411.79 47.11 44.96 10.18c 5.29 47.02
Total clearance including low pH 412.05 411.85 411.79 412.02 44.96 10.18c 5.29 47.02
a Figures in bold are used for calculation of total clearance.
b Even more effective reduction of WNV by 46.32 log10 was achieved when S/D treatment was combined with C-18 chromatography for removal of S/D.
c Reduction of 10.18 log10 Parvo virus achieved by fraction IIIþdepth ﬁltration (PPV) and 35 nm virus ﬁltration (BPV).
Table 2
Virus removal (log10) by precipitation and removal of fraction III at different pH,
followed by depth ﬁltration.
Virus pH 5.15 pH 5.25 pH 5.45
PPV 4.00 4.02 44.20
MEV 5.29 5.29 45.55
Fig. 2. Inactivation of BVDV, SinV and PRV by TNBP/Triton X-100 at combined
worst case conditions (0.2/0.8%, 25.570.5 1C and pH 6.2070.05). BVDV run B was
performed at pH 4.50. Inactivation below the limit of detection of all viruses was
achieved after 8 min treatment. The demonstrated inactivation values depend on
the titer of the stocks of the different test viruses.
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fraction III supernatant
Conditions for validating the combined steps of fraction III
precipitation and depth ﬁltration (Cuno) of the fraction III super-
natant were essentially the same as those used for each step
performed separately. Precipitation was performed at varied pH
(pH 5.15, 5.25 and 5.45) to test pH values above and below the
target pH for their effect in removing PPV and MEV. Of these
variations, pH changes were the only parameters that had a
signiﬁcant effect on virus removal. The minimum virus removal
values at pH 5.15 are reported in Table 1. Non-enveloped viruses,
i.e. PPV and MEV are removed by Z4.0 log10 at the worst case
conditions tested. As shown in Table 2, pH can inﬂuence the
efﬁcacy of virus removal by this step.
3.4. Solvent-detergent treatment
For S/D treatment, validation studies were performed using the
lower limit of S/D concentration in IVIG manufacturing. The pH in
validation studies was elevated to pH 6.20 to avoid any inactivation
by low pH. The temperature was reduced to 25.5 1C, to below the
minimum used in production. S/D inactivation was stopped by
treating the test sample with C-18 Sepharose beads to remove the
S/D reagents. Viruses were rapidly inactivated by S/D to below
the limit of detection (Fig. 2). Inactivation of all test viruses was in
the range of 44 to 47 log10 and the results are summarized
in Table 1.
3.5. 35 nm Virus ﬁltration
Virus ﬁltration studies were performed at high and low pH and
with an excess of test sample with respect to ﬁlter surface area.
Values at high pH were reported in Table 1. The data show that
35 nm ﬁltration removed signiﬁcant titers of all the enveloped
viruses tested (HIV, PRV and BVDV) and also of non-envelopedviruses (BPV and SV40), depending on the size of the virus
particles. Although BPV is small (18–24 nm), BPV virus particles
are complexed with antibodies to Parvovirus B19 and their
effective diameter is increased.4. Discussion
4.1. Virus inactivation and removal
During plasma fractionation, classes of proteins are precipi-
tated and separated from proteins in solution by centrifugation or
ﬁltration. Viruses are distributed into the ﬁbrinogen precipitate
(Cohn–Oncley fraction I) and the IgG fraction (Cohn–Oncley
fractions IIþ III). The most effective virus removal step during
cold ethanol fractionation to produce IgG is precipitation of
fraction III [4]. This step was investigated at worst case condi-
tions, i.e. reduced concentration of ethanol (15% instead of 17%),
elevated temperature (4 1C instead of 5 1C), reduced amount
of ﬁlter aid and reduced ﬁlter area per volume.
The virus reduction data observed in this study showed that
fraction III precipitation and removal by centrifugation when
combined with the clariﬁcation by depth ﬁltration in the presence
of a ﬁlter aid was effective in removing two non-enveloped
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A virus, i.e. PPV and MEV. Of these variations, pH changes were
the only parameters that had an effect on virus removal. For each
virus tested, the reduction in virus levels in the fraction III
supernatant at pH 5.45 was greater than at pH 5.15. For the
combination of precipitation of fraction III and depth ﬁltration,
less virus removal (PPV¼4.00 log10; MEV¼5.29 log10) was
observed at the lowest pH tested and virus removal increased
as the pH increased (Table 2). However, even at the lowest pH an
effective removal of PPV by 4 log10 was demonstrated.
Solvent/detergent virus inactivation of enveloped viruses has
been used to produce safe plasma products since 1985 when it
was licensed in the manufacture of factor VIII, a product that
carried a high risk of transmitting blood-borne viruses in the past,
before speciﬁc virus inactivation steps were introduced. In 1985
and before, Horowitz and his group reported that the solvent/
detergent process was an effective virus inactivation process
for plasma derivatives, including IGIV [5–8]. Subsequently, virus
inactivation by solvent/detergent was incorporated into other
products [9–11]. S/D treatment in this study was performed at
worst case conditions, i.e. reduced concentrations of TNBP and
Triton X-100 (0.2% and 0.8% instead of 0.3% and 1.0%), reduced
temperature of 25.5 1C (instead of 28 1C) and short incubation
time of 2 h. In addition, the pH was increased to neutral range.
Inactivation of enveloped viruses by S/D is fast and inactivation
below the limit of detection is achieved after few minutes of
treatment (Fig. 2). The S/D inactivation data reported in this study
conﬁrm the robust inactivation of enveloped viruses reported in
the literature for IGIV and other plasma derivatives [12].
Low pH is not a designated virus inactivation step in the
production process of Biotest IGIV. However, several steps in the
production process are performed at low pH, e.g. S/D treatment. The
potential inﬂuence of low pH on virus inactivation during S/D
treatment was investigated. Testing was done using the same
conditions as for S/D treatment but without the addition of S/D
reagents. The protein concentration was elevated, the temperature
was lowered to 25.5 1C and the pH was adjusted to the upper
production limit of pH 4.5. As shown in Table 1, PRV and Sindbis
virus were inactivated by 3.2 log10 and 4.91 log10, respectively (Fig. 3).
Not inactivated at pH 4.50 were BVDV and MEV. Inactivation of the
other test viruses (no kinetics tested) ranged from o1 to 2.43 log10.
Low pH inactivation was ﬁrst observed by Reid et al. in 1988
[13], who reported that enveloped viruses such as Vaccinia,
herpes simplex (HSV), mumps and Semliki Forest virus (SFV)
were inactivated by pepsin treatment at pH 4. The data were
conﬁrmed by Kempf and others [14–16]. The data in this study
conﬁrm previous observations that incubation of IgG solutions atFig. 3. Inactivation of BVDV, PRV SinV and MEV at pH 4.570.05 and 2570.5 1C.
Inactivation below the limit of detection was not achieved. Residual infectivity
was detected in all samples. Bench controls at pH 6.20 for BVDV: 0.3 log10, for
PRV: 1.14 log10, for SinV: 0.0 log10, for MEV: 0.43 log10.low pH inactivates some enveloped viruses but is less effective or
even ineffective for non-enveloped viruses.
Virus ﬁltration is a simple, robust, non-destructive process
that adds size exclusion to conventional virus inactivation and
partitioning procedures. The use of ﬁltration with deﬁned pore
sizes in the nanometer range for removal of adventitious viruses is
the ﬁrst major advance in virus elimination since development
of solvent-detergent procedures. As shown in Table 1, ﬁltration
performed in validation studies reported here removed all of the
enveloped viruses studied (HIV, PRV and BVDV) but also a small
non-enveloped virus, BPV. Although BPV is 18–24 nm in size,
removal of viruses smaller than the nominal pore size of the
nanoﬁlter was due to antibody-complexed virus particles [17–19].
The results presented here demonstrate that the production
process of Biotest IGIV employs three effective steps for inactiva-
tion and/or removal of enveloped and non-enveloped viruses.
Virus reduction is caused by different mechanisms of action, thus
viruses, which might escape one procedure, are inactivated or
removed by one of the subsequent procedures. In addition to the
three virus inactivating/removing steps, low pH, although not a
dedicated inactivation step, can also contribute to virus inactiva-
tion of some sensitive viruses in a limited range.
Guidelines on virus validation for plasma derivatives [1,2]
require a capacity of virus removal and inactivation, which can
reliably remove a potential load of adventitious viruses. Virus
inactivation or removal of enveloped viruses of at least 4.0 log10
by two steps and for non-enveloped viruses by one step of is
considered as sufﬁcient. The virus validation results for the IGIV
presented here fulﬁlls those requirements.
In conclusion, the robust virus removal and inactivation
procedures used in Biotest Pharmaceuticals IGIV production
remove the enveloped and non-enveloped blood-borne viruses
that are known today and has the potential to remove a broad
range of emerging pathogens that might contaminate future
blood supplies. The three virus inactivation and/or removal
procedures described here show high efﬁcacy in inactivation
and/or removal of test viruses and relevant viruses and in
combination with selection of donors, careful screening serologi-
cally and by NAT, a virus safe ﬁnal IGIV product results.
4.2. Prion removal
The production process of Biotest IGIV employs several steps,
which are capable to remove prions. Those steps are cold ethanol
fractionation, nanoﬁltration and column chromatography [20–22],
as reported in abundance in the literature. However, product speciﬁc
studies on the removal of prions were not performed, as Biotest IGIV
is produced from US plasma only. In the US until today not a single
native case of variant Creutzfeldt Jakob Disease (vCJD) was reported.
Consequently, the probability of a plasma donation at risk for vCJD
entering a plasma pool is extremely low. The risk R, calculated using
the formula R¼1(1–p)n [23], is less than 1 donation at risk per
100,000 plasma pools for a prevalence p of o1 case of vCJD per
305,000,000 US residents and plasma pools of n¼3000 donations.
Therefore the risk of a vCJD donation in an US plasma pool can be
considered as theoretical only. In case of such an unlikely event, the
production steps have sufﬁcient capacity to remove prions.Acknowledgments
This research was supported in its entirety by Biotest AG,
Dreieich, Germany and Biotest Pharmaceuticals, Boca Raton,
FL, USA.
We also thank NewLab; Cologne, Germany for excellently
performing the studies on HIV, WNV and BPV, and all technicans
H.O. Dichtelmu¨ller et al. / Results in Immunology 2 (2012) 19–2424in the Pathogen Safety Lab at Biotest Dreieich. The technical
support provided by John Hooper (BioCatalyst LLC, Liberty,
Missouri, USA) is greatfully appreciated.
References
[1] Guidelines on viral inactivation and removal procedures intended to assure
the viral safety of human blood plasma products; WHO Technical Report
series no. 924, 2004.
[2] Guideline on Plasma Derived Medicinal Products; CPMP/BWP/269/95, rev. 3,
25 January 2001.
[3] Cavalli-Sforza L. Biometrie Grundzuge Biologisch-medizinischer Statistik
[Biometry, the basics of biological and medical statistics]. Stuttgart: Gustav
Fischer; 1974. [p. 171–3].
[4] Dichtelmu¨ller HO, Biesert L, Fabbrizzi F, Falbo A, Flechsig E, Gro¨ner A, et al.
Contribution to safety of immunoglobulin and albumin from virus partition-
ing and inactivation by cold ethanol fractionation: a data collection from
Plasma Protein Therapeutics Association member companies. Transfusion
2011;51:1412–30.
[5] Prince AM, Horowitz B, Horowitz MS, Zang E. The development of virus-free
labile blood derivatives—a review. European Journal of Epidemiology
1987;3:103–18.
[6] Prince AM, Horowitz B, Brotman B, Huima T, Richardson L, van den Ende M.
Inactivation of Hepatitis B and Hutchinson strain non-A, non-B hepatitis
viruses by exposure to Tween 80 and ether. Vox Sanguinis 1984;46:36–43.
[7] Prince AM, Horowitz B, Dichtelmu¨ller H, Stephan W, Gallo RC. Quantitative
assays for evaluation of HTLV III inactivation procedures: tri(N-butyl)
phosphate:sodium cholate and b-propiolactone. Cancer Research 1985;45:
4592s–94ss.
[8] Horowitz B, Wiebe ME, Lippin A, Stryker MHG. Inactivation of viruses in
labile blood products I. Disruption of lipid enveloped viruses by tri (n-butyl)
phosphate detergent combinations. Transfusion 1985;25:516–22.
[9] Alonso WR, Trukawinski S, Savage M, Tenold RA, Hammond DJ. Viral inactiva-
tion of intramuscular immune serum globulins. Biologicals 2000;28:5–15.
[10] Biesert L. Virus validation studies of immunoglobulin preparations. Clinical
and Experimental Rheumatology 1996;14(Suppl. 15):s47–52.
[11] Rabenau HF, Biesert L, Schmidt T, Bauer G, Cinatl J, Doerr HW. SARS-corona
virus (SARS-CoV) and the safety of a solvent/detergent treated immunoglo-
bulin preparation. Biologicals 2005;33:95–9.[12] Dichtelmu¨ller HO, Biesert L, Fabbrizzi F, Gajardo R, Gro¨ner A, von Hoegen I,
et al. Robustness of solvent/detergent treatment of plasma derivatives: a
data collection from Plasma Protein Therapeutics Association member
companies. Transfusion 2009;49:1931–43.
[13] Reid KG, Cuthbertson B, Jones ADL, McIntosh RV. Potential contribution of
mild pepsintreatment at pH 4 to the viral safety of human immunoglobulin
products. Vox Sanguinis 1988;55:75–80.
[14] Omar A, Kempf C, Immelmann A, Rentsch M, Morgenthaler JJ. Virus
inactivation by pepsin treatment at pH 4 of IgG solutions: factors affecting
the rate of virus inactivation. Transfusion 1996;36:866–72.
[15] Louie RE, Galloway CJ, Dumas ML, Wong MF, Mitra G. Inactivation of
hepatitis C virus in low pH intravenous immunoglobulin. Biologicals 1994;
22:13–9.
[16] Bos OJM, Sunye DGJ, Nieuweboer CEF, van Engelenburg FAC, Schuitemaker H,
Over J. Virus validation of pH 4-treated human immunoglobulin products
produced by the Cohn Fractionation Process. Biologicals 1998;26:267–76.
[17] Troccoli NM, McIver J, Losikoff A, Poiley J. Removal of viruses from human
intravenous immune globulin by 35 nm nanoﬁltration. Biologicals 1998;26:
321–9.
[18] Caballero S, Nieto S, Gajardo R, Jorquera JI. Viral safety characteristics of
Flebogammas DIF, a new pasteurized, solvent-detergent treated and Planova
20 nm nanoﬁltered intravenous immunoglobulin. Biologicals 2010;38:
486–93.
[19] Poelsler G, Berting A, Kindermann J, Spruth M, Ha¨mmerle T, Teschner W,
et al. A new liquid intravenous immunoglobulin with three dedicated virus
reduction steps: virus and prion reduction capacity. Vox Sanguinis 2008;94:
184–92.
[20] Lee DC, Stenland CJ, Miller JLC, Cai K, et al. A direct relationship between
partitioning of the pathogenic prion protein and transmissible spongiform
encephalopathy infectivity during the puriﬁcation of plasma proteins.
Transfusion 2000;41:449–55.
[21] Foster PR, Welch AG, McLean C, Grifﬁn BD, et al. Distribution of a bovine
spongiform encephalopathy – derived agent over ion – exchange chromato-
graphy used in the preparation of concentrates of ﬁbrinogen and factor VIII.
Vox Sanguinis 2004;86:92–9.
[22] Yunoki M, Tanaka H, Urayama T, Hattori S, et al. Prion removal by
nanoﬁltration under different experimental conditions. Biologicals 2008;
36(1):27–36.
[23] Brown P. Donor pool size and the risk of blood-borne Creutzfeldt–Jakob
disease. Transfusion 1998;38(3):312–5.
